TRVI
Trevi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.26
+1.17%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−41.9x
Market Cap
$2.46B
MomentumView details →
1D Return
+1.17%
YTD Return
+35.22%
RSI (14)
41.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−41.9x
Market Cap
$2.46B
RSI (14)
41.4
MomentumView details →
1D Return
+1.17%
YTD Return
+35.22%
SummaryUpdated Jun 1, 2026
Trevi Therapeutics, Inc. (NASDAQ:TRVI) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in New Haven, Connecticut. The company went public in May 2019 and focuses exclusively on developing <b>Haduvio</b>, an oral extended-release formulation of nalbuphine, to treat serious neurologically mediated conditions. Trevi operates under a licensing agreement with Endo Pharmaceuticals Inc. for the development and commercialization of nalbuphine hydrochloride-based products. The company is currently advancing multiple Phase 2 clinical trials targeting chronic cough conditions, representing a significant unmet medical need in respiratory medicine.
Similar companies
Latest newsMore news →
Trevi Therapeutics announced that Professor Marlies Wijsenbeek will present quality-of-life outcomes from the Phase 2b CORAL trial of nalbuphine ER at the ERS Congress 2026.9d agoTrevi Therapeutics began two clinical trials in Q2 2026 and plans to launch a third study in Q3 2026 for nalbuphine ER (Haduvio) in chronic-cough indications.28d agoMichael Heffernan was elected as a Class I director of Trevi Therapeutics, Inc., effective June 3, 2026.93d ago